TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. It focuses on the manufacture of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded on January 24, 2018 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

National Institute of Health/National Institute of Allergy and Infectious Disease Direct to Phase II SBIR Grant Will Fund Preclinical and IND Enabling Studies on a Shelf-Stable Mucosal Delivered Universal Flu Vaccine Using Thin Film Freezing

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

FORT WORTH, Texas, May 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will be presenting a corporate overview at the 2023 Jefferies Healthcare Conference being held in-person in New York, NY on June 7-9, 2023. Company management will also be participating in one-on-one meetings on Friday June 9th at the conference.

TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

FORT WORTH, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter of 2023.

TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

FORT WORTH, Texas, May 04, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulations of high molecular weight hyaluronan (HMW-HA) for treating or preventing respiratory diseases. Today's agreement follows prior research which showed that HMW-HA formulated with Thin Film Freezing yielded dry powder formulations that possess desirable aerosol performance.

TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems (PPB) program to develop next-generation countermeasures for military and healthcare personnel.

TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program

FORT WORTH, Texas, March 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported fourth quarter and full year 2022 financial results.

TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results

FORT WORTH, Texas, March 06, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that CEO Harlan Weisman, M.D. will be participating in a Fireside Chat at the 35th Annual Roth Conference being held in-person at The Ritz Carlton, Laguna Niguel in Dana Point on March 12-14, 2023. Company management will also be participating in one-on-one meetings throughout the conference.

TFF Pharmaceuticals to Participate in the 35th Annual Roth Conference

The Real Good Food Co

Steakholder Foods Ltd

Who doesn't love a bargain? We look for deals in many places.

3 Bargain Stocks Worth Buying at These 52-Week Lows

Dr. Harlan Weisman and recently appointed Chief Medical Officer Dr. Zamaneh Mikhak to Provide an Overview of the Corporate Strategy and 2023 Objectives

TFF Pharmaceuticals Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

FORT WORTH, Texas, Jan. 09, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced the appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer. Dr. Mikhak will be responsible for the clinical development of the Company's pipeline candidates, including the Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder clinical programs.

TFF Pharmaceuticals Announces the Appointment of Zamaneh Mikhak, M.D. as Chief Medical Officer

Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors

TFF Pharmaceuticals Announces Leadership Transition

Underwriters Exercise Their Option in Full Underwriters Exercise Their Option in Full

TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

Charah Solutions Inc

Canoo

Heliogen

Porch Group

Satsuma Pharmaceuticals Inc

Venus Concept

7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 7 Insider Picks In November

Penny stock picks from insiders in November 2022. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 Insider Picks In November

Almost everything has gone wrong since my first bullish article with TFF Pharmaceuticals. The stock is now severely depressed and, despite significant dilution, a case can be made for a speculative long position.

TFF Pharmaceuticals: From Undefeatable To Speculative

New York, New York--(Newsfile Corp. - November 19, 2022) - Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether TFF and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP

FORT WORTH, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it has priced a $10.675 million underwritten offering of 9,282,609 shares of its common stock and warrants to purchase up to 4,641,305 shares of common stock. The warrants are being sold at the rate of one warrant for every two shares of common stock. The public offering price, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant is $1.15. All of the securities in the offering were sold by the TFF Pharmaceuticals, Inc. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering price, less underwriting discounts and commissions. The offering is expected to close on Tuesday, November 22, 2022.

TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants

FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it is offering to sell shares of its common stock and warrants to purchase common stock in an underwritten public offering. All of the securities in the offering are being sold by the TFF Pharmaceuticals, Inc. In addition, the company intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the number of shares and warrants offered at the public offering price, less underwriting discounts and commissions. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether the offering may be completed, or as to the actual size and terms of the offering. The offering is expected to price on or about Thursday, November 17, 2022.

TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Dale Christensen - Head, Clinical Development Kirk Coleman - CFO, Treasurer & Secretary Robert Williams - Technology Inventor & Special Advisor Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Vernon Bernardino - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Greetings, and welcome to the TFF Pharmaceuticals, Inc. Third Quarter 2022 Earnings Conference Call.

TFF Pharmaceuticals, Inc. (TFFP) Q3 2022 Earnings Call Transcript

Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI)

TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TFF Pharmaceuticals, Inc. - TFFP

Company conference call and webcast at 4:30 PM ET

TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022

Administration of dry powders will utilize Aptar Pharma's Unidose (UDS) Powder Nasal Spray System

TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics

Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology

TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced program updates for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) clinical programs.

News for TFF Pharmaceuticals Stock (TFFP)